Outlook Therapeutics is building its U.S. commercial organization around LYTENAVA, following the drug’s FDA approval for wet age-related macular degeneration. The company has added senior commercial ...
Conferencia de resultados del T3 de 2026 de Axsome Therapeutics (AXSM): los ingresos aumentan un 52%
Los ingresos de Axsome Therapeutics en el tercer trimestre de 2026 aumentaron un 52 % hasta los 259,7 millones de dólares, ya ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results